PostEra

Medicinal Chemistry powered by Machine Learning

Chief of Staff at PostEra

$125k - $175k / 0.05% - 0.10%
Location
Boston, MA / Remote
Job Type
Full-time
Experience
1+ years
Connect directly with founders of the best YC-funded startups.
Apply to role ›
Alpha Lee
Alpha Lee
Founder

About the role

What is the role?

Basically, we're looking for a rock star generalist. You'll be working as the first business hire along with our CEO to help PostEra run efficiently and grow quickly. The priorities for now will be:

  • Managing PostEra's recruitment pipeline and interview process; helping us attract and recruit the top talent in the world for Chemistry, Engineering and Machine Learning.
  • Overseeing the current People functions and employee experience.
  • Working with PostEra's accounting, legal and finance partners to ensure smooth operations.
  • Assisting with external engagements such as preparing presentation materials for PostEra Board and client presentations.
  • Be a cross-functional team member and support day-to-day operations of the company; willing to “roll up sleeves” with a “no task is too small” mentality.
  • Augment the 'PostEra culture', diagnose issues and help us improve the way drug discovery is done.

Required

  • A military attitude toward organisation and efficiency; a self-starter with strong project management and communication skills.
  • You’ve got high EQ, excellent judgment, discretion, and grace under pressure.
  • 2 - 3y operational experience in a fast-paced startup/small company.
  • Demonstrated ownership over company processes and designing/launching new initiatives.
  • Comfortable with quantitative work and analytical approaches to solve problems; proficiency with Excel, Powerpoint and general business software.

Bonus Points

  • Experience managing and running a recruitment pipeline leveraging various software platforms.
  • Scientific degree such as Chemistry, Biology or Biotech experience
  • Financial modelling experience
  • Familiarity with python or strong interest to leverage automated/coding skills

About PostEra

PostEra offers medicinal chemistry powered by machine learning

PostEra is a Y Combinator-backed company using machine learning, applied to medicinal chemistry, to expedite the discovery of new drugs and get new cures to patients.

What are we working on?

The answer is many things but here's our top priorities right now:

  • Partnerships: We partner with drug hunters and help them get cures to patients faster. We're currently collaborating with Pfizer and several small biotechs, using all of PostEra's ML to help their drug discovery.
  • Manifold: The first-of-its-kind SaaS platform for scientists to get molecules made.
  • COVID Moonshot: PostEra is helping lead the world's largest open-source drug discovery effort. Moonshot is an international team of scientists working on an antiviral cure for COVID and in 1 year we've gone from ideas on a website to potent compounds which should soon be ready for human trials preparation.

Why you should join PostEra

PostEra offers Medicinal Chemistry powered by Machine Learning

Drug discovery R&D is slow and expensive and this limits biotechs and pharma from getting new drugs into development and new cures to patients. PostEra is building an end-to-end med chem platform to advance drug discovery and serve the world's ever expanding community of drug hunters.

We've raised $26M from top tech/healthcare investors and signed large multi-year deals with companies like Pfizer.

What are we working on?

The answer is many things but here's our top priorities right now:

  • Partnerships: We partner with drug hunters and help them get cures to patients faster. We're currently collaborating with Pfizer and several small biotechs, using all of PostEra's ML to help their drug discovery.
  • Manifold: The first-of-its-kind SaaS platform for scientists to get molecules made.
  • COVID Moonshot: PostEra is helping lead the world's largest open-source drug discovery effort. Moonshot is an international team of scientists working on an antiviral cure for COVID and in 1 year we've gone from ideas on a website to potent compounds which should soon be ready for human trials.